Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Monoclonal antibodies are complex and expensive to produce, meaning poor countries might be priced out.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

As the race to develop a vaccine against COVID-19 rages on, some researchers are focused on a short-term way to treat people with the disease: monoclonal antibodies. Rather than wait for vaccines to coax the body to make its own antibodies, these scientists want to inject designer versions of these molecules to directly disable the SARS-CoV-2 coronavirus. But mass-produced antibodies, routinely used to treat diseases such as cancer, are complex to manufacture and come with a hefty price tag. That risks placing them beyond the reach of poor countries.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 584, 333-334 (2020)

doi: https://doi.org/10.1038/d41586-020-02360-y

Updates & Corrections

  • Correction 12 August 2020: An earlier version of this story incorrectly said that the median price for antibody therapies in the United States is US$15,000–$200,000 per treatment. In fact, this is the cost per year of treatment.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links